ReproNovo Achieves First Dosing Milestone in EU Phase 2 NORDIC Trial for RPN-002 in ART

First-participant dosing in a randomized EU Phase 2 trial signals that ReproNovo's oxytocin receptor antagonist RPN-002 has cleared the EMA clinical trial authorisation threshold and entered active human evaluation, a checkpoint that carries manufacturing and quality implications for any oral small-molecule entering European sites.

The NORDIC study (EU CT Number: 2025-524896-22) is a randomized, placebo-controlled, double-blind, parallel-group, multicenter trial enrolling 120 participants across five European sites. The protocol investigates two dosing regimens of RPN-002, nolasiban, at higher doses and over a longer administration schedule than previously studied, targeting uterine contractility and endocrine parameters around embryo transfer in IVF and ICSI programs. The primary objective is pharmacodynamic evidence to support optimized regimen selection for subsequent efficacy trials.

For QA directors and regulatory leads overseeing clinical supply chains, the transition to higher-dose cohorts in a multicenter European setting raises familiar considerations around comparator sourcing, investigational medicinal product (IMP) release testing, and site-level GMP compliance under EU Annex 13. Oral small-molecule formulations entering Phase 2 at modified dose levels typically require updated process characterization data to support the clinical trial dossier, particularly where pharmacodynamic endpoints depend on consistent plasma exposure.

ReproNovo's broader pipeline context is relevant to operations teams tracking capacity commitments: the company has four Phase 2 readouts planned over the next two years, spanning RPN-002 for embryo implantation and adenomyosis, and RPN-001 for male infertility associated with low testosterone. Parallel program advancement at this scale places concurrent demand on clinical manufacturing slots, stability programs, and regulatory submission timelines across jurisdictions.

Enrollment completion across five European sites, and the pharmacodynamic dataset it generates, will determine whether RPN-002 advances to a pivotal implantation-rate study, the outcome that will define the regulatory and manufacturing investment required at the next stage.

Source: ReproNovo via GlobeNewswire, 6 July 2026.